Literature DB >> 20449639

The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action.

Chih-Min Yang1, Yi-Zih Liu, Jiunn-Wang Liao, Miao-Lin Hu.   

Abstract

This study examined the anti-metastatic effects of oxythiamine (OT) both in cell culture and in vivo. Cell culture results revealed that OT (0-20 microM) significantly inhibited the invasion and migration (IC(50) = 8.75 microM) of Lewis lung carcinoma (LLC) cells. These effects of OT were accompanied by the inhibition of metalloproteinases-2 and -9 (MMP-2, MMP-9), urokinase-type plasminogen activator (uPA) activities and by the increases in protein expression of tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1, TIMP-2). We then implanted (s.c.) C57BL/6 mice with LLC cells and supplemented the mice with a low- or a high-dose of OT (250 or 500 mg/kg BW) daily for 5 wk. During the 5-wk period, OT supplementation decreased plasma MMP-2 activity in a dose-dependent manner, and this effect was significant after 4 wk of tumor cell implantation. Tumor metastasis was found to confine to the lungs of mice injected with the tumor cells. High-OT supplementation strongly lowered the number and area of tumors and inhibited protein expression of MMP-2 and MMP-9 in the lungs. In addition, high-OT supplementation markedly decreased the extent of proliferating cell nuclear antigen (PCNA) staining in the lungs. By contrast, OT supplementation increased TIMP-1 and -2 protein expression in the lungs. These results demonstrate that OT supplementation attenuates tumor cell metastasis, possibly via inhibition of protein expression of MMPs, extent of PCNA staining and via increase of proteins expression of TIMPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20449639     DOI: 10.1007/s10585-010-9331-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  26 in total

1.  Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 2.  Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).

Authors:  M J Duffy; K McCarthy
Journal:  Int J Oncol       Date:  1998-06       Impact factor: 5.650

3.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

Review 4.  Activation mechanisms of matrix metalloproteinases.

Authors:  H Nagase
Journal:  Biol Chem       Date:  1997 Mar-Apr       Impact factor: 3.915

Review 5.  Gelatinase-mediated migration and invasion of cancer cells.

Authors:  Mikael Björklund; Erkki Koivunen
Journal:  Biochim Biophys Acta       Date:  2005-04-12

Review 6.  Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

Authors:  Mark Bloomston; Emmanuel E Zervos; Alexander S Rosemurgy
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

7.  Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action.

Authors:  L G Boros; J L Brandes; F I Yusuf; M Cascante; R D Williams; W J Schirmer
Journal:  Med Hypotheses       Date:  1998-06       Impact factor: 1.538

8.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

9.  Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies.

Authors:  B A Robbins; D de la Vega; K Ogata; E M Tan; R M Nakamura
Journal:  Arch Pathol Lab Med       Date:  1987-09       Impact factor: 5.534

10.  Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice.

Authors:  M Watanabe; Y Takahashi; T Ohta; M Mai; T Sasaki; M Seiki
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

View more
  8 in total

1.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

2.  Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.

Authors:  Carmela Ricciardelli; Noor A Lokman; Sowmya Cheruvu; Izza A Tan; Miranda P Ween; Carmen E Pyragius; Andrew Ruszkiewicz; Peter Hoffmann; Martin K Oehler
Journal:  Clin Exp Metastasis       Date:  2015-04-21       Impact factor: 5.150

3.  Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.

Authors:  Chin-Shiu Huang; Shih-Chieh Lyu; Miao-Lin Hu
Journal:  Invest New Drugs       Date:  2011-08-09       Impact factor: 3.850

Review 4.  Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug.

Authors:  Simone Cardaci; Enrico Desideri; Maria Rosa Ciriolo
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

5.  A dose- and time-dependent effect of oxythiamine on cell growth inhibition in non-small cell lung cancer.

Authors:  Lin Bai; Hui-Li Zhu
Journal:  Cogn Neurodyn       Date:  2021-11-09       Impact factor: 3.473

Review 6.  Thiamine and selected thiamine antivitamins - biological activity and methods of synthesis.

Authors:  Adam Tylicki; Zenon Łotowski; Magdalena Siemieniuk; Artur Ratkiewicz
Journal:  Biosci Rep       Date:  2018-01-10       Impact factor: 3.840

7.  Linking vitamin B1 with cancer cell metabolism.

Authors:  Jason A Zastre; Rebecca L Sweet; Bradley S Hanberry; Star Ye
Journal:  Cancer Metab       Date:  2013-07-24

8.  Effect of siRNA-mediated gene silencing of transketolase on A549 lung cancer cells.

Authors:  Huan Lu; Huili Zhu
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.